HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LFCR
Lifecore Biomedical, Inc.
There isn't enough reported data to score LFCR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LFCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Stable | |
| Weak |
LFCR's cash flow is currently stable, but its profitability and balance sheet are weak. There isn't enough data to rate its revenue.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LFCR PE Valuation
LFCR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LFCR Forward outlook
There aren't enough analyst estimates for LFCR to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus LFCR down 490%.
LFCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.16 | +$0.11 |
| Q2 2025 | -$1.27 | -497% |
| Q1 2025 | -$1.39 | -$0.53 |
| Q4 2024 | -$0.50 | +$2.11 |
| Q3 2024 | $0.14 | +$3.56 |
| Q2 2024 | $0.32 | +$3.77 |
| Q1 2024 | -$0.86 | +$3.11 |
| Q4 2023 | -$2.61 | +$0.46 |
LFCR is still losing money, but far less than before: $1.95 per share over the past year, against $3.97 at its worst in early 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LFCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
LFCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.3M | -19% |
| Q2 2026 | $34.2M | -6.2% |
| Q1 2026 | $23.2M | -34% |
| Q4 2025 | $44.4M | +36% |
| Q3 2025 | $31.1M | +26% |
| Q2 2025 | $36.4M | -3.8% |
| Q1 2025 | $35.2M | -1.5% |
| Q4 2024 | $32.6M | +8% |
LFCR's revenue has slid since its 2020 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.5% | +6.3 points |
| Q2 2026 | 7.5% | -7.1 points |
| Q1 2026 | -20% | +5.5 points |
| Q3 2025 | -9.9% | +37 points |
| Q2 2025 | 15% | +8.9 points |
| Q1 2025 | -26% | -23 points |
| Q4 2024 | -6% | -1.1 points |
| Q3 2024 | -47% | -12 points |
LFCR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LFCR on cash flow, with more consistent year-over-year improvement.
LFCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6M | +24036% |
| Q2 2026 | -$2.7M | -183% |
| Q1 2026 | $3.6M | +$7.8M |
| Q4 2025 | -$986.3K | +$7.6M |
| Q3 2025 | $25K | +$4.1M |
| Q2 2025 | $3.3M | -62% |
| Q1 2025 | -$4.3M | +$3.5M |
| Q4 2024 | -$8.6M | -$5.6M |
LFCR's free cash flow has turned positive after six years mostly in the red: $6M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LFCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LFCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +271K shares |
| 1 year | +1.2% | +443K shares |
| 3 years | +24% | +7.4M shares |
| 5 years | +29% | +8.4M shares |
| Available history | +30% | +8.7M shares |
LFCR has 38M diluted shares, up 1.2% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LFCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | 5,820.6x | High |
| Q3 2021 | 8.2x | High |
| Q2 2021 | 25.7x | High |
| Q4 2019 | 8.5x | High |
LFCR's net debt is more than 20 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LFCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 90.1 | Overbought |
LFCR's weekly RSI is 61 (neutral) and its Stochastic is 90 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LFCR PE vs Healthcare Sector
| Metric | LFCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFCR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LFCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.2% above |
| 20 week MA | $5.21 | 23% above |
| 50 week MA | $5.85 | 9.4% above |
| 100 week MA | $6.38 | 0.3% above |
| 200 week MA | $6.45 | 0.8% below |
LFCR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LFCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $10.1 | -12% |
| 2021 | $10.1 | $11.0 | +8.7% |
| 2022 | $11.0 | $6.93 | -37% |
| 2023 | $6.93 | $6.19 | -11% |
| 2024 | $6.19 | $7.28 | +18% |
| 2025 | $7.28 | $8.30 | +14% |
| 2026 YTD | $8.30 | $6.40 | -23% |
LFCR has the edge over HIMS on returns for 2026, with the stronger performance.